Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.

Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print Cited Medium: Internet ISSN: 2376-1032 (Electronic) Linking ISSN: 23760540 NLM ISO Abbreviation: J Manag Care Spec Pharm Subsets: MEDLINE

Original Publication: Alexandria, VA : Academy of Managed Care Pharmacy, [2014]-

Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/epidemiology ; Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use ; Glucagon-Like Peptide-1 Receptor*/agonists; Adult ; Humans ; Glucose ; Hypoglycemic Agents ; Medically Underserved Area ; Obesity/complications ; Retrospective Studies ; Sodium ; Sulfonylurea Compounds ; United States

BACKGROUND: Evidence from clinical trials shows that newer second-line diabetes medications-glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is)-have cardio-renal protective effects in addition to their glucose-lowering properties. Despite strong evidence of benefits, there is limited evidence regarding prescribing patterns for these medications, especially among populations at high risk for disparities. OBJECTIVE: To examine the associations of cardio-renal and obesity comorbidities and neighborhood factors with the prescribing of GLP-1RAs or SGLT2is in comparison with dipeptidyl peptidase 4 inhibitors (DPP-4is) or sulfonylureas (SFUs) and for each of the newer second-line diabetes medications (GLP-1RA vs DPP-4i, SGLT2i vs DPP-4i, GLP-1RA vs SFU, and SGLT2i vs SFU) in medically underserved populations. METHODS: A retrospective cohort study was conducted using electronic medical records from a health care delivery system that serves medically underserved populations in the Mid-South region of the United States. Metformin-treated adult patients with type 2 diabetes, and at least 1 prescription for GLP-1RA, SGLT2i, DPP-4i, or SFU class medications, were identified between April 2016 and August 2021. Neighborhood factors were assessed at the census tract level by geocoding and linking patient addresses to neighborhood-level risk factors. Using multilevel logistic regression models, we examined the associations of comorbidities and neighborhood factors with the prescription of newer second-line diabetes medications. RESULTS: 7,723 patients received newer second-line diabetes medications, with 16% prescribed GLP-1RAs, 11% prescribed SGLT2is, 28% prescribed DPP-4is, and 45% prescribed SFUs. Patients with cerebrovascular disease were significantly less likely to receive newer second-line diabetes medications (odds ratio [OR] = 0.65, 95% CI = 0.52-0.80). Patients with obesity were more likely to receive newer second-line diabetes medications (OR = 1.68, 95% CI = 1.48-1.90). Living in neighborhoods with higher proportions of college graduates was associated with a higher likelihood of receiving newer second-line diabetes medications (quartile 3 vs 1: OR = 1.30, 95% CI = 1.06-1.59; and quartile 4 vs 1: OR = 1.46, 95% CI = 1.13-1.88). CONCLUSIONS: Our findings demonstrate substantial underprescribing and significant clinical and neighborhood variations in the use of newer second-line diabetes medications. We found lower use of newer second-line diabetes medications among patients with cerebrovascular disease and higher use in those with obesity. Our findings also suggest that newer second-line diabetes medications are first adopted by those in higher socioeconomic groups, thus increasing disparities in care. DISCLOSURES: Dr Surbhi reports grants or contracts from the Tennessee Department of Health, Agency for Healthcare Research and Quality, and PhRMA Foundation. Dr Bailey reports honoraria from the SouthEast Texas Chapter of the American College of Healthcare Executives, leadership or fiduciary role in the Coalition for Better Health and The Healthy City, Inc., and stock or stock options in Proctor and Gamble, Walmart, and Apple. Dr Kovesdy reports personal fees from Bayer, Abbott, AstraZeneca, Takeda, Tricida, Akebia, Cara Therapeutics, Vifor, Rockwell, CSL Behring, Boehringer Ingelheim, and GSK, outside the submitted work. The other authors report no conflicts of interest.

JAMA Netw Open. 2021 Apr 1;4(4):e216139. (PMID: 33856475)
Int J Health Geogr. 2012 Nov 09;11:48. (PMID: 23137192)
JAMA. 2018 Apr 17;319(15):1580-1591. (PMID: 29677303)
JAMA Netw Open. 2021 Feb 1;4(2):e2035792. (PMID: 33523188)
JAMA Cardiol. 2021 Feb 1;6(2):148-158. (PMID: 33031522)
Lancet Reg Health Eur. 2022 Jan 25;14:100308. (PMID: 35146474)
N Engl J Med. 2017 Aug 17;377(7):644-657. (PMID: 28605608)
JAMA Health Forum. 2021 Dec 17;2(12):e214182. (PMID: 35977298)
Int J Cardiol. 2015;187:547-52. (PMID: 25863300)
Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-S157. (PMID: 36507650)
Diabetes Care. 2021 Aug 4;:. (PMID: 34348996)
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. (PMID: 31422062)
Sci Rep. 2019 Sep 10;9(1):13009. (PMID: 31506585)
Lancet. 2000 Sep 23;356(9235):1093-8. (PMID: 11009159)
J Am Heart Assoc. 2021 Jul 6;10(13):e021084. (PMID: 33998258)
BMC Endocr Disord. 2022 Apr 26;22(1):111. (PMID: 35473607)
Diabetologia. 2021 Feb;64(2):349-360. (PMID: 33078206)
J Diabetes Complications. 2022 Jun;36(6):108204. (PMID: 35537891)
Lancet. 2019 Jan 5;393(10166):31-39. (PMID: 30424892)
J Cardiovasc Pharmacol. 2020 Sep;76(3):313-320. (PMID: 32569016)
Diabetes Care. 2018 Dec;41(12):2669-2701. (PMID: 30291106)
Womens Health Issues. 2016 Mar-Apr;26(2):201-7. (PMID: 26809487)
Am J Prev Cardiol. 2022 Aug 02;11:100370. (PMID: 35968531)
Am Heart J. 2020 Jun;224:47-53. (PMID: 32304879)
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110. (PMID: 31862752)
Innov Pharm. 2019 Oct 31;10(4):. (PMID: 34007585)
Diabet Med. 2022 Sep;39(9):e14898. (PMID: 35694847)
BMC Prim Care. 2022 May 24;23(1):124. (PMID: 35606699)
BMJ. 2012 Jan 10;344:d7771. (PMID: 22236411)
N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978)
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10929-34. (PMID: 12140364)
Lancet. 2019 Jul 13;394(10193):121-130. (PMID: 31189511)
Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. (PMID: 34964831)
Pharmacol Res. 2021 Sep;171:105782. (PMID: 34302978)
BMJ. 2021 Jan 13;372:m4573. (PMID: 33441402)
J Am Board Fam Med. 2018 May-Jun;31(3):342-350. (PMID: 29743218)
N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427)
Kidney Int. 2020 Oct;98(4S):S1-S115. (PMID: 32998798)
Diabetes Care. 2023 Jan 1;46(Suppl 1):S158-S190. (PMID: 36507632)
Am Heart J. 2022 Jun;248:160-162. (PMID: 34968441)
Am J Manag Care. 2020 Jul 1;26(7):e211-e218. (PMID: 32672919)
Diabet Med. 2019 Apr;36(4):444-452. (PMID: 30653708)

0 (Dipeptidyl-Peptidase IV Inhibitors)
0 (Glucagon-Like Peptide-1 Receptor)
IY9XDZ35W2 (Glucose)
0 (Hypoglycemic Agents)
9NEZ333N27 (Sodium)
0 (Sulfonylurea Compounds)

Date Created: 20230605 Date Completed: 20230613 Latest Revision: 20230801

20230801

PMC10387916

10.18553/jmcp.2023.29.6.699

37276038